Epistasis between toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to crohn's disease

American Journal of Gastroenterology

Volumn 104, Issue 7, 2009, Pages 1723-1733

  Török, Helga P ^a   Glas, Jürgen ^a,b   Endres, Ilona ^b   Tonenchi, Laurian ^a,b   Teshome, Molla Y ^b,c   Wetzke, Martin ^b   Klein, Wolfram ^d   Lohse, Peter ^a   Ochsenkühn, Thomas ^a   Folwaczny, Matthias ^b   Göke, Burkhard ^a   Folwaczny, Christian ^b   Müller Myhsok, Bertram ^e   Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c JIMMA UNIVERSITY   (Ethiopia)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERLEUKIN 23 RECEPTOR; TOLL LIKE RECEPTOR 9;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE PREDISPOSITION; DLG5 GENE; EPISTASIS; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IBD5 GENE; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; NOD2 GENE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; EPISTASIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GERMANY; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROBABILITY; PROGNOSIS; RECEPTORS, INTERLEUKIN; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TOLL-LIKE RECEPTOR 9; YOUNG ADULT;

EID: 67650514274     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.184     Document Type: Article

References (55)

1. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leu-cine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
2. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 ;411: 603-6.
3. Hampe J, Cuthbert A, Croucher PJ et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
4. Cario E. Bacterial interactions with cells of the intestinal mucosa: toll-like rceptors and NOD2. Gut 2005;54:1182-93.
5. Török HP, Glas J, Tonenchi L et al. Polymorphisms of the lipopolysaccha-ride-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004;112:85-91.
6. Brand S, Staudinger T, Schnitzler F et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005;11:645-52.
7. Browning BL, Huebner C, Petermann I et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 2007;102:2504-12.
8. De Jager PL, Franchimont D, Waliszewska A et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007;8:387-97.
9. Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of pep-tidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-72.
10. Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. 1 Biol Chem 2003;278:5509-12.
11. van Heel DA, Ghosh S, Butler M et al. Muramyl dipeptide and tolllike receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005;365:1794-6.
12. van Heel DA, Ghosh S, Hunt KAetal. SynergybetweenTLR9andNOD2 innate immune responses is lost in genetic Crohn's disease. Gut 2005;54: 1553-7.
13. Lee J, Mo JH, Katakura K etal. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006;8:1327-36.
14. Rachmilewitz D, Karmeli F, Takabayashi K et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterol-ogy 2002;122:1428-41.
15. Rachmilewitz D, Katakura K, Karmeli F et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-8.
16. Obermeier F, Strauch UG, Dunger N et al. In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis. Gut 2005;54:1428-36.
17. Obermeier F, Dunger N, Strauch UG et al. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology 2005;129:913-27.
18. Hampe J, Lynch NJ, Daniels S et al. Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease. Gut 2001;48: 191-7.
19. Satsangi J, Parkes M, Louis E et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996;14:199-202.
20. Lazarus R, Klimecki WT, Raby BA et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three US ethnic groups and exploratory case-control disease association studies. Genomics 2003;81:85-91.
21. Török HP, Glas J, Tonenchi L et al. Crohn's disease is associated with a tolllike receptor-9 polymorphism. Gastroenterology 2004;127:365-6.
22. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3.
23. Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207-11.
24. Rioux JD, Daly MJ, Silverberg MS et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001;29:223-8.
25. Peltekova VD, Wintle RF, Rubin LA et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004;36:471-5.
26. Stoll M, Corneliussen B, Costello CM et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004;36:476-80.
27. Stange EF, Travis SP, Vermeire S et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55 (Suppl 1): il-15.
28. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53.
29. Glas J, Seiderer J, Wetzke M et al. rsl004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS ONE 2007;2:e819.
30. Glas J, Konrad A, Schmechel S et al. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population. Am J Gastroenterol 2008;103:682-91.
31. Török HP, Glas J, Tonenchi L et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 2005;54: 1421-7.
32. Seiderer J, Brand S, Herrmann KA et al. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. Inflamm Bowel Dis 2006;12:1114-21.
33. Browning BL, Annese V, Barclay ML et al. Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. J Med Genet 2008;45:36-42.
34. Economou M, Trikalinos TA, Loizou KT et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004;99:2393-404.
35. Rumio C, Besusso D, Palazzo M et al. Degranulation of paneth cells via tolllike receptor 9. Am J Pathol 2004;165:373-81.
36. Lala S, Ogura Y, Osborne C et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003;125:47-57.
37. Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004;53:1658-64.
38. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
39. Yen D, Cheung J, Scheerens H et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006;116:1310-6.
40. Seiderer J, Elben I, Diegelmann J et al. Role of the novel Th 17 cytokine IL-17F in inflammatory bowel disease (IBD): Upregulated colonic IL-17F expression in active crohn's disease and analysis of the IL17F p.His161 Arg polymorphism in IBD. Inflamm Bowel Dis 2008;14:437-45.
41. Brand S, Beigel F, Olszak T et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006;290:G827-38.
42. Dambacher J, Beigel F, Golluscio R et al. The novel IL-10 related cytokine IL-26 is increased in active inflammatory bowel disease and intestinal epithelial cells express the functional IL-26 receptor complex. Gastroenterology 2006;130:A196.
43. Brand S, Olszak T, Beigel F et al. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem 2006;97:709-23.
44. Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology 2007;133:1327-39.
45. Beynon V, Cotofana S, Brand S et al. NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes. Inflamm Bowel Dis 2008;14:1033-40.
46. Mannon PJ, Fuss IT, Mayer L et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79.
47. Cummings JR, Ahmad T, Geremia A et al. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflamm Bowel Dis 2007;13:1063-8.
48. Seiderer J, Glas J, Diegelmann J et al. The first two Crohn's disease susceptibility loci with a high degree of epistasis: PTGER4-expression-modulating polymorphisms in the 5pl3.1 region enhance ATG16L1-associated susceptibility to Crohn's disease. Gastroenterology 2008;134:A456.
49. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-62.
50. Cunningham-Rundles C, Radigan L, Knight AK et al. TLR9 activation is defective in common variable immune deficiency. J Immunol 2006;176:1978-87.
51. Novak N, Yu CF, Bussmann C et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 2007;62:766-72.
52. Noguchi E, Nishimura F, Fukai H et al. An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy 2004;34:177-83.
53. Ito A, Ota M, Katsuyama Y et al. Lack of association of Toll-like receptor 9 gene polymorphism with Behcet's disease in Japanese patients. Tissue Antigens 2007;70:423-6.
54. Hur JW, Shin HD, Park BL et al. Association study of Toll-like receptor 9 gene polymorphism in Korean patients with systemic lupus erythematosus. Tissue Antigens 2005;65:266-70.
55. De Jager PL, Richardson A, Vyse TJ et al. Genetic variation in toll-like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis Rheum 2006;54:1279-82.